Compare TOP & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOP | NVAX |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2021 | 1996 |
| Metric | TOP | NVAX |
|---|---|---|
| Price | $16.73 | $9.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 143.3K | ★ 4.2M |
| Earning Date | 01-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 81.25 | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | $4,723,765.00 | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 41.89 | ★ 64.69 |
| 52 Week Low | $0.61 | $6.20 |
| 52 Week High | $16.35 | $11.85 |
| Indicator | TOP | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 79.37 | 58.65 |
| Support Level | $1.01 | $8.42 |
| Resistance Level | N/A | $8.99 |
| Average True Range (ATR) | 1.17 | 0.41 |
| MACD | 0.11 | 0.14 |
| Stochastic Oscillator | 92.61 | 65.28 |
TOP Financial Group Ltd is operates as an online brokerage firm in Hong Kong specializing in the trading of local and overseas equities, futures, and options products. It conduct the futures and stock brokerage business through three trading platforms, Esunny for futures trading and Longbridge for stock trading, all of which were licensed from third parties and can be easily accessed through its application, or APP, software, and websites. The three platforms are designed for seamless, efficient, and secure trading platform. The company operates and manages its business as a single operating and reportable segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.